PegBio Co., Ltd.

2565

CNE100006T44

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 11:08:30 11/06/2026 +03			5-day change	1st Jan Change
7.530 ^HKD	-1.31%		-7.04%	-89.09%

06-08	PegBio Receives HK$61 Million in Royalty Payment Over Drug Licensing Deal	MT
05-26	259,880,839 H Shares of PegBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 26-MAY-2026.	CI

PegBio Wins China Nod for Hong Kong Share Full Circulation

Published on 04/10/2026 at 05:29 am +03

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about PegBio Co., Ltd.

06-08	PegBio Receives HK$61 Million in Royalty Payment Over Drug Licensing Deal	MT
05-26	259,880,839 H Shares of PegBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 26-MAY-2026.	CI
05-19	Pegbio Co., Ltd. Announces Resignation of Xinpeng Fan as Independent Non-Executive Director, the Chairperson of the Audit Committee, and A Member of Each of the Remuneration and Appraisal Committee and the Nomination Committee with Effect from May 19, 2026	CI
04-10	PegBio Wins China Nod for Hong Kong Share Full Circulation	MT
04-02	PegBio Co., Ltd. Announces Research Abstract Related to CR059 Accepted by the 2026 Scientific Sessions of the American Diabetes Association	CI
04-01	Pegbio Co., Ltd. Announces Change of Joint Company Secretary, Authorised Representative, and Process Agent, Effective April 1, 2026	CI
03-24	PegBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-23	PegBio Co posts FY loss attributable RMB208.4 million	RE
03-23	Harbour BioMed Reports Online Publication Of Phase I Results For HBM9378	CI
03-23	PegBio Trims Losses in 2025	MT
03-17	PegBio Partners With Tenry Pharma to Commercialize Paidakang in China; Shares Jump 7%	MT
03-16	PegBio enters exclusive commercialization collaboration with Tenry Pharmaceutical for Paidakang in mainland China	RE
03-16	Pegbio Co., Ltd. and Shanghai Tenry Pharmaceutical Co., Ltd. Enter Exclusive Commercialization Collaboration for Paidakang in Mainland China with Aggregate Commercialization Sales Target of over Rmb 10,000 Million and Royalty of Approximately Hkd 140 Million	CI
03-09	PegBio's GLP-1 Candidate Completes First-in-Human Dosing	MT
03-06	PegBio Co., Ltd. Announces Completion Of First-In-Human Trial For Next-Generation GLP-1	CI

PegBio Co Ltd is a China-based company principally engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).

Employees

Sector

Pharmaceuticals

More about the company